$2.040
+0.030 (+1.49%)收盤時
- High
- 2.160
- Open
- 2.160
- VWAP
- 2.05
- Vol
- 244.95K
- Mkt Cap
- 11.00M
- Low
- 1.940
- Amount
- 501.33K
- EV/EBITDA, TTM
- 0.00
Organovo Holdings, Inc. is a biotechnology company that focuses on building high fidelity, three-dimensional (3D) tissues that recapitulate various aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. It is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease (CD). The Company uses its technology to build functional 3D human tissues that mimic various aspects of native human tissue composition, architecture, function, and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Its 3D human tissue platform is multifaceted.
Analyst Ratings (3)
估值指標
事件時間軸
資訊
7.506-11TipRanksDouble Dose of AI Drug Deals Fails to Give Novo Nordisk Stock (NVO) a Boost
9.004-24NewsfilterVivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market
- 5.004-23Newsfilter
VivoSim to Carry Forward Organovo 3D Bioprinting
9.004-11BenzingaWhy Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
- 7.004-02Newsfilter
Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements
ONVO FAQ — answered by Alphio AI
Organovo Holdings, Inc. is a biotechnology company that focuses on building high fidelity, three-dimensional (3D) tissues that recapitulate various aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. It is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease (CD). The Company uses its technology to build functional 3D human tissues that mimic various aspects of native human tissue composition, architecture, function, and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Its 3D human tissue platform is multifaceted. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
3 analysts cover ONVO: 2 rate it Buy, 1 Hold and 0 Sell.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。